Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Has results × Advanced Cancer × Standard of Care × Clear all

Sponsor

Conditions

Breast Neoplasms 11 Pancreatic Neoplasms 6 Prostatic Neoplasms 5 Ovarian Neoplasms 5 Leukemia, Myeloid, Acute 5 Head and Neck Neoplasms 5 Urinary Bladder Neoplasms 4 Neoplasms 4 Multiple Myeloma 4 Lung Neoplasms 4 Leukemia 4 Recurrence 3 Neoplasms, Plasma Cell 3 Colorectal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Rectal Neoplasms 2 Radiodermatitis 2 Neoplasms by Site 2 Myelodysplastic Syndromes 2 Melanoma 2 Hematologic Neoplasms 2 Gastrointestinal Neoplasms 2 Carcinoma, Transitional Cell 2 Urologic Neoplasms 1 Urologic Diseases 1 Urogenital Neoplasms 1 Urinary Bladder Diseases 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1

Interventions

Nivolumab 7 linrodostat 3 Ipilimumab 3 relatlimab 2 Pemetrexed 2 tislelizumab 1 regorafenib 1 ralimetinib 1 p38 Mitogen-Activated Protein Kinases 1 figitumumab 1 efatutazone 1 abemaciclib 1 Vorinostat 1 Tamoxifen 1 Sunitinib 1 Ranitidine 1 Midazolam 1 LY2603618 1 LY2584702 1 Gemcitabine 1 Fulvestrant 1 Dasatinib 1 Crizotinib 1 Cetuximab 1 Carboplatin 1 BMS-813160 1 3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡